📊 CRBU Key Takeaways
Is Caribou Biosciences, Inc. (CRBU) a Good Investment?
Caribou Biosciences faces critical fundamental distress with $27.0M annual operating cash burn against only $12.1M cash reserves, yielding approximately 5.4 months of runway. Revenue generation of $2.4M is insufficient to offset $26.3M operating losses, and flat net income growth despite revenue gains signals deteriorating unit economics. Without immediate major financing or dramatic operational improvement, the company faces existential liquidity risk within two quarters.
Caribou Biosciences shows modest revenue growth, but its fundamentals remain dominated by extreme operating losses, deeply negative margins, and substantial cash burn. The balance sheet is helped by no long-term debt and strong near-term liquidity ratios, but the low cash balance relative to negative operating and free cash flow raises concern about funding durability and the quality of growth.
Caribou Biosciences, Inc. Key Strengths (CRBU)
- Zero long-term debt provides balance sheet flexibility
- Excellent short-term liquidity ratios (6.22x current/quick)
- Modest revenue traction ($2.4M) demonstrates early commercialization
- Debt-free capital structure reduces financial leverage risk
- Strong current and quick ratios indicate near-term balance sheet flexibility
- Revenue is growing year over year, showing some commercial or collaboration progress
CRBU Stock Risks: Caribou Biosciences, Inc. Investment Risks
- Critical cash runway of ~5.4 months at current burn rate ($27M annual operating cash outflow vs $12.1M cash)
- Operating losses of $26.3M dwarf $2.4M revenue, yielding -1096% operating margin and -1046% net margin
- Flat net income YoY despite 11.7% revenue growth indicates worsening unit economics and inability to scale profitably
- Operating and net margins are extremely negative, indicating an unsustainable cost structure
- Operating cash flow and free cash flow are deeply negative, implying continued cash burn
- Cash and equivalents appear low relative to annual losses, increasing financing risk if burn does not improve
Key Metrics to Watch
- Cash balance and monthly burn rate trajectory
- Quarterly revenue growth and gross margin expansion
- Operating cash flow inflection point
- Quarterly operating cash burn versus cash and equivalents
- Revenue growth relative to R&D and operating expense trends
Caribou Biosciences, Inc. (CRBU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.22x current ratio provides a solid financial cushion.
CRBU Profit Margin, ROE & Profitability Analysis
CRBU vs Healthcare Sector: How Caribou Biosciences, Inc. Compares
How Caribou Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Caribou Biosciences, Inc. Stock Overvalued? CRBU Valuation Analysis 2026
Based on fundamental analysis, Caribou Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Caribou Biosciences, Inc. Balance Sheet: CRBU Debt, Cash & Liquidity
CRBU Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Caribou Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 10% decline. The most recent EPS of $-1.65 indicates the company is currently unprofitable.
CRBU Revenue Growth, EPS Growth & YoY Performance
CRBU Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.4M | -$25.1M | $-0.26 |
| Q3 2025 | $2.0M | -$27.5M | $-0.30 |
| Q2 2025 | $2.7M | -$37.7M | $-0.42 |
| Q1 2025 | $2.4M | -$40.0M | $-0.43 |
| Q3 2024 | $2.0M | -$10.0M | $-0.12 |
| Q2 2024 | $3.5M | -$28.0M | $-0.42 |
| Q1 2024 | $2.4M | -$28.0M | $-0.46 |
| Q3 2023 | $3.3M | -$10.0M | $-0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Caribou Biosciences, Inc. Dividends, Buybacks & Capital Allocation
CRBU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Caribou Biosciences, Inc. (CIK: 0001619856)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRBU
What is the AI rating for CRBU?
Caribou Biosciences, Inc. (CRBU) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRBU's key strengths?
Claude: Zero long-term debt provides balance sheet flexibility. Excellent short-term liquidity ratios (6.22x current/quick). ChatGPT: Debt-free capital structure reduces financial leverage risk. Strong current and quick ratios indicate near-term balance sheet flexibility.
What are the risks of investing in CRBU?
Claude: Critical cash runway of ~5.4 months at current burn rate ($27M annual operating cash outflow vs $12.1M cash). Operating losses of $26.3M dwarf $2.4M revenue, yielding -1096% operating margin and -1046% net margin. ChatGPT: Operating and net margins are extremely negative, indicating an unsustainable cost structure. Operating cash flow and free cash flow are deeply negative, implying continued cash burn.
What is CRBU's revenue and growth?
Caribou Biosciences, Inc. reported revenue of $2.4M.
Does CRBU pay dividends?
Caribou Biosciences, Inc. does not currently pay dividends.
Where can I find CRBU SEC filings?
Official SEC filings for Caribou Biosciences, Inc. (CIK: 0001619856) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRBU's EPS?
Caribou Biosciences, Inc. has a diluted EPS of $-0.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CRBU's fundamental grade?
Based on our AI fundamental analysis in June 2026, Caribou Biosciences, Inc. has a C grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CRBU stock overvalued or undervalued?
Valuation metrics for CRBU: ROE of -24.6% (sector avg: 15%), net margin of -1,046.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CRBU's AI grade for 2026?
Our dual AI analysis gives Caribou Biosciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRBU's free cash flow?
Caribou Biosciences, Inc.'s operating cash flow is $-27.0M, with capital expenditures of $72.0K. FCF margin is -1,128.7%.
How does CRBU compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,046.5% (avg: 12%), ROE -24.6% (avg: 15%), current ratio 6.22 (avg: 2).